What’s the current market cap for Alvotech stock?

Alvotech (ALVO) has a market cap of $1.2bn as of June 21, 2026.

What is the P/E ratio for Alvotech stock?

The price to earnings (P/E) ratio for Alvotech (ALVO) stock is 0 as of June 21, 2026.

Does Alvotech stock pay dividends?

No, Alvotech (ALVO) stock does not pay dividends to its shareholders as of June 21, 2026.

When is the next Alvotech dividend payment date?

Alvotech (ALVO) stock does not pay dividends to its shareholders.

What is the beta indicator for Alvotech?

Alvotech (ALVO) has a beta rating of 0.21. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

Buy Alvotech stock | $ALVO Share Price

About Alvotech

Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.

Ticker

$ALVO

Sector

Health

Primary listing

NASDAQ

Employees

1,279

Headquarters

Luxembourg, Luxembourg

Website

www.alvotech.com

Alvotech Metrics

BasicAdvanced

$1.2bn

-

-$0.28

0.21

-

Bulls say / Bears say

Alvotech’s adjusted EBITDA rose 19% to $24.4 million in Q1 2026, driven by a favorable revenue mix and regulatory guidance allowing earlier capitalization, expanding the EBITDA margin to 23% despite a topline decline (Reuters via Investing.com).

The company reaffirmed its 2026 full-year guidance, targeting $650–700 million in revenues and $180–220 million in adjusted EBITDA, underscoring management’s confidence in its recovery trajectory (Reuters via Investing.com).

In mid-June 2026, Alvotech secured approximately $152 million in gross proceeds through a public offering and concurrent private placement priced at $3.75 per share, bolstering liquidity to fund its biosimilar pipeline advancement (Reuters via Investing.com).

First-quarter 2026 revenues plunged 20.2% year-over-year to $105.9 million, missing analysts’ expectations of $130.9 million and weighing on investor sentiment as shares neared 52-week lows after the report (Reuters via Investing.com).

The company’s balance sheet reflects heightened financial risk, with net debt increasing to $1.393 billion and leverage at 9.9× adjusted EBITDA, while cash balances fell to $63.8 million as of March 31, 2026, constraining financial flexibility (Reuters via Investing.com).

Ongoing facility improvement projects at its Reykjavik manufacturing site led to production slowdowns in Q1, raising concerns about supply reliability and potential delays for commercial launches (Reuters via Investing.com).

Data summarised monthly by Lightyear AI. Last updated on 20 Jun 2026.

Alvotech News

AllArticlesVideos

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

About Alvotech

Ticker

Employees

Headquarters

Alvotech Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Alvotech News

Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions

Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End

Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End

Buy $ALVO

Lightyear

Legal

Work with us

Bulls say / Bears say

Alvotech/$ALVO

About Alvotech

Ticker

Employees

Headquarters

Alvotech Metrics

Price and volume

Financial strength

Profitability

Management effectiveness

Valuation

Growth

Bulls say / Bears say

Alvotech News

Alvotech Hits Critical Inflection as Biosimilar Pipeline Nears FDA Decisions

Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End

Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End

What’s the current market cap for Alvotech stock?

What is the P/E ratio for Alvotech stock?

Does Alvotech stock pay dividends?

When is the next Alvotech dividend payment date?

What is the beta indicator for Alvotech?

Bulls say / Bears say